Induced pluripotent stem cell: Difference between revisions

From WikiMD's Wellness Encyclopedia

← Older editNewer edit →
CSV import
CSV import
Line 1: Line 1:
'''Induced pluripotent stem cells''' ('''iPSCs''') are a type of [[pluripotent stem cell]] that can be generated directly from adult cells. The iPSC technology was first developed in 2006 by [[Shinya Yamanaka]]'s team at Kyoto University, Japan. They demonstrated that the introduction of four specific genes encoding transcription factors could convert adult cells into pluripotent stem cells. This groundbreaking discovery has significant implications for [[regenerative medicine]], [[drug discovery]], and the study of [[disease modeling]].
{{Short description|Stem cells generated from adult cells}}
{{Use dmy dates|date=October 2023}}


<youtube>
'''Induced pluripotent stem cells''' ('''iPSCs''') are a type of [[pluripotent stem cell]] that can be generated directly from adult cells. The iPSC technology was pioneered by [[Shinya Yamanaka]] and his team in 2006, for which he was awarded the [[Nobel Prize in Physiology or Medicine]] in 2012. This breakthrough has significant implications for regenerative medicine, disease modeling, and drug discovery.
title='''{{PAGENAME}}'''  
movie_url=http://www.youtube.com/v/ahTjpXPVjQg
&rel=1
embed_source_url=http://www.youtube.com/v/ahTjpXPVjQg
&rel=1
wrap = yes
width=750
height=600
</youtube>


==Overview==
==History==
Induced pluripotent stem cells are adult cells that have been genetically reprogrammed to an embryonic stem cell-like state by being forced to express genes and factors important for maintaining the defining properties of embryonic stem cells. Although these cells are similar to embryonic stem cells in many respects, iPSCs are not derived from embryos. Instead, they are typically derived from adult somatic cells, such as skin or blood cells. This method of generating pluripotent cells bypasses ethical concerns associated with the use of embryonic stem cells.
The concept of reprogramming adult cells to a pluripotent state was first demonstrated by Yamanaka and his colleagues, who introduced four specific genes encoding transcription factors into adult [[fibroblasts]]. These factors, known as the "Yamanaka factors," include [[Oct4]], [[Sox2]], [[Klf4]], and [[c-Myc]]. The introduction of these factors reprograms the adult cells into a pluripotent state, similar to that of [[embryonic stem cells]].


==Generation of iPSCs==
==Characteristics==
The original method for creating iPSCs involved the introduction of four specific transcription factors: [[Oct4]], [[Sox2]], [[Klf4]], and [[c-Myc]], collectively known as the Yamanaka Factors. These factors are introduced into the cells using viral vectors, although newer methods have been developed that use non-integrating approaches to avoid potential genomic instability.
[[File:Stem cell diagram.svg|thumb|right|Diagram of stem cell differentiation.]]
Induced pluripotent stem cells share many characteristics with embryonic stem cells, including the ability to differentiate into any cell type of the three germ layers: ectoderm, mesoderm, and endoderm. This pluripotency makes them a valuable tool for studying development and disease.
 
===Pluripotency===
Pluripotency refers to the ability of a stem cell to differentiate into any cell type of the body. iPSCs exhibit this property, making them a powerful tool for regenerative medicine. They can be used to generate [[neurons]], [[cardiomyocytes]], [[hepatocytes]], and many other cell types.
 
===Self-renewal===
Like embryonic stem cells, iPSCs have the ability to self-renew indefinitely in culture. This property allows for the generation of large quantities of cells for research and therapeutic purposes.


==Applications==
==Applications==
#Regenerative Medicine
[[File:Stem cell research.jpg|thumb|left|Stem cell research in a laboratory setting.]]
iPSCs hold great promise for regenerative medicine because they can be differentiated into various cell types, including neurons, heart muscle cells, and pancreatic beta cells. This capability makes them a potential source for cell replacement therapies to treat diseases such as [[Parkinson's disease]], [[diabetes]], and [[heart disease]].
The ability to generate patient-specific iPSCs has opened new avenues in personalized medicine. iPSCs can be used to model diseases, screen drugs, and potentially provide autologous cell therapies.
 
===Disease Modeling===
By generating iPSCs from patients with specific genetic disorders, researchers can create disease models in vitro. These models help in understanding the pathophysiology of diseases and in identifying potential therapeutic targets.
 
===Drug Discovery===
iPSCs provide a platform for high-throughput drug screening. By testing compounds on iPSC-derived cells, researchers can identify drugs that may be effective in treating specific diseases.


#Drug Discovery and Toxicology
===Regenerative Medicine===
iPSCs can be used to generate disease-specific cell models, which are valuable for drug discovery and toxicology studies. These models can help identify new drug targets and screen for potential drug toxicity, reducing the reliance on animal models.
The potential to generate patient-specific cells for transplantation offers a promising avenue for regenerative medicine. iPSCs could be used to replace damaged tissues in conditions such as [[Parkinson's disease]], [[diabetes]], and [[heart disease]].


#Disease Modeling
==Challenges==
iPSCs can be derived from patients with specific genetic disorders. By differentiating these iPSCs into cell types relevant to the disease, researchers can study the disease mechanisms at the cellular level, potentially leading to new insights and treatments.
Despite their potential, iPSCs face several challenges. The reprogramming process can introduce genetic and epigenetic abnormalities. Additionally, the use of oncogenes like c-Myc raises concerns about tumorigenicity.


==Ethical Considerations==
==Ethical Considerations==
The development of iPSC technology has addressed some of the ethical concerns associated with embryonic stem cell research, as iPSCs can be generated without the need for embryos. However, ethical considerations still exist, particularly regarding the potential for genetic modifications and the long-term effects of iPSC-derived therapies.
The use of iPSCs circumvents many ethical issues associated with embryonic stem cells, as they do not require the destruction of embryos. However, ethical considerations regarding genetic manipulation and potential clinical applications remain.


==Challenges and Limitations==
==Related pages==
Despite their potential, the use of iPSCs is not without challenges. Issues such as the efficiency of cell reprogramming, the stability of the reprogrammed cells, and the risk of tumorigenesis due to the use of oncogenes like c-Myc in the reprogramming process are areas of ongoing research.
* [[Stem cell]]
* [[Embryonic stem cell]]
* [[Regenerative medicine]]
* [[Shinya Yamanaka]]


==Future Directions==
[[Category:Stem cells]]
Research on iPSCs is rapidly advancing, with efforts focused on improving the efficiency and safety of iPSC generation, understanding the mechanisms underlying pluripotency and differentiation, and developing new applications for these cells in medicine and research.
 
[[Category:Cell biology]]
[[Category:Regenerative medicine]]
[[Category:Regenerative medicine]]
[[Category:Stem cells]]
{{Medicine-stub}}
<gallery>
File:Human_induced_pluripotent_stem_cell_colony_(51816035910).jpg|Human induced pluripotent stem cell colony
File:Human_iPS_cells_colonies.png|Human iPS cells colonies
File:Dedifferentiation_Methods_(2010)_-_Bischoff,_Steven_R.tif|Dedifferentiation Methods (2010) - Bischoff, Steven R.
File:Induction_of_iPS_cells.svg|Induction of iPS cells
File:Production_of_iPSC_Timeline.png|Production of iPSC Timeline
File:Three_germ_line_cells_differentiated_from_iPSCs.png|Three germ line cells differentiated from iPSCs
</gallery>

Revision as of 17:31, 18 February 2025

Stem cells generated from adult cells



Induced pluripotent stem cells (iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. The iPSC technology was pioneered by Shinya Yamanaka and his team in 2006, for which he was awarded the Nobel Prize in Physiology or Medicine in 2012. This breakthrough has significant implications for regenerative medicine, disease modeling, and drug discovery.

History

The concept of reprogramming adult cells to a pluripotent state was first demonstrated by Yamanaka and his colleagues, who introduced four specific genes encoding transcription factors into adult fibroblasts. These factors, known as the "Yamanaka factors," include Oct4, Sox2, Klf4, and c-Myc. The introduction of these factors reprograms the adult cells into a pluripotent state, similar to that of embryonic stem cells.

Characteristics

File:Stem cell diagram.svg
Diagram of stem cell differentiation.

Induced pluripotent stem cells share many characteristics with embryonic stem cells, including the ability to differentiate into any cell type of the three germ layers: ectoderm, mesoderm, and endoderm. This pluripotency makes them a valuable tool for studying development and disease.

Pluripotency

Pluripotency refers to the ability of a stem cell to differentiate into any cell type of the body. iPSCs exhibit this property, making them a powerful tool for regenerative medicine. They can be used to generate neurons, cardiomyocytes, hepatocytes, and many other cell types.

Self-renewal

Like embryonic stem cells, iPSCs have the ability to self-renew indefinitely in culture. This property allows for the generation of large quantities of cells for research and therapeutic purposes.

Applications

File:Stem cell research.jpg
Stem cell research in a laboratory setting.

The ability to generate patient-specific iPSCs has opened new avenues in personalized medicine. iPSCs can be used to model diseases, screen drugs, and potentially provide autologous cell therapies.

Disease Modeling

By generating iPSCs from patients with specific genetic disorders, researchers can create disease models in vitro. These models help in understanding the pathophysiology of diseases and in identifying potential therapeutic targets.

Drug Discovery

iPSCs provide a platform for high-throughput drug screening. By testing compounds on iPSC-derived cells, researchers can identify drugs that may be effective in treating specific diseases.

Regenerative Medicine

The potential to generate patient-specific cells for transplantation offers a promising avenue for regenerative medicine. iPSCs could be used to replace damaged tissues in conditions such as Parkinson's disease, diabetes, and heart disease.

Challenges

Despite their potential, iPSCs face several challenges. The reprogramming process can introduce genetic and epigenetic abnormalities. Additionally, the use of oncogenes like c-Myc raises concerns about tumorigenicity.

Ethical Considerations

The use of iPSCs circumvents many ethical issues associated with embryonic stem cells, as they do not require the destruction of embryos. However, ethical considerations regarding genetic manipulation and potential clinical applications remain.

Related pages

Retrieved from "https://wikimd.com/index.php?title=Induced_pluripotent_stem_cell&oldid=6328341"